Major depressive disorder (MDD) and treatment-resistant depression (TRD) remain inadequately addressed by current antidepressants, which have limited efficacy or undesirable side effects linked to their actions on monoamine neurotransmitters (serotonin, norepinephrine, dopamine). New drugs targeting non-monoamine pathways, such as the recently approved intranasal Esketamine (a glutamatergic agent) combined with an oral antidepressant for adult TRD, offer promise. Several glutamatergic and GABAergic drugs are in clinical development, and preliminary positive trial results with psychedelics like psilocybin, Ayahuasca, 5-MeO-DMT, and LSD suggest they may become effective therapies. Expanding beyond monoamine targets appears to yield antidepressants with superior efficacy, safety, and tolerability.
Before psychedelic-assisted therapy can be integrated into mainstream medicine, a thorough understanding of its risks and adverse effects is critical. Current clinical trials have left knowledge gaps, and a comprehensive analysis of human receptor pharmacology is needed to guide safe dosing and identify drug-drug interactions with common antidepressants, antipsychotics, and anticonvulsants. Post-approval pharmacovigilance will be essential for patient safety, and future trials must include more ethnically diverse populations. This innovation in psychiatry requires careful, stepwise safety and risk-benefit evaluations to maximize patient benefit.